Cassava ends simufilam Alzheimer’s programme after second Phase III failure
While investigations into the drug are stopping in Alzheimer’s disease, the therapy is now being evaluated in TSC-related ...
Fierce Biotech8d
Cassava stops Alzheimer's program as simufilam fails another phase 3
Cassava Sciences has given up on simufilam in Alzheimer’s disease. | Cassava Sciences has given up on simufilam in ...
MPR6d
Simufilam Fails in Second Alzheimer Disease Trial Ending Development Program
Topline results were announced from a phase 3 trial evaluating simufilam, an oral small molecule that targets the filamin A protein, for the treatment of mild to moderate Alzheimer disease (AD).
Zacks.com on MSN2d
Is the Future Bleak for SAVA Stock Following Another Setback?
The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with ...
BioSpace8d
Cassava Finally Ends Alzheimer’s Program for Embattled Simufilam
Cassava Sciences has officially ended development of simufilam in Alzheimer’s disease, marking the end of a tumultuous era ...
Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop
Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments.
pharmaphorum7d
End of the line for Cassava's troubled Alzheimer's programme
The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...
Cassava Sciences to discontinue all efforts to develop simufilam in Alzheimer’s
We are disappointed that the results of REFOCUS-ALZ and RETHINK-ALZ showed no treatment benefit for patients with mild-to-moderate Alzheimer’s ...
Cassava Sciences: Downside From Alzheimer's Results Still Possible Despite New Developments
Cassava Sciences explores simufilam's potential for seizures in tuberous sclerosis. Results for Alzheimer's trials expected ...